ArticleHeart and vessels2026
Impact of right bundle branch block in anterior ST-segment elevation myocardial infarction in the contemporary primary PCI era.
Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum albumin in cancer survivors with heart failure: beyond a static prognostic marker.Heart and vessels · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of right bundle branch block (RBBB) has long been recognized as a risk factor for poor prognosis, particularly in patients with anterior ST-segment elevation myocardial infarction (STEMI). However, in the contemporary era of primary percutaneous coronary intervention (PCI), the prognostic significance of RBBB in anterior STEMI has not been fully clarified. This retrospective study aimed to investigate the association between RBBB and clinical outcomes in anterior STEMI patients treated with primary PCI. The primary endpoint was major adverse cardiovascular events (MACE), defined as a composite of all-cause death, non-fatal myocardial infarction, or readmission for heart failure. We included 632 patients and divided them into the RBBB group (n = 96) and non-RBBB group (n = 536). Patients with RBBB were older and had higher Killip class, lower systolic blood pressure, higher peak creatine kinase levels, and lower left ventricular ejection fraction. Proximal left anterior descending artery lesions and chronic total occlusion in non-culprit arteries were more frequent in the RBBB group. In-hospital MACE and mortality were significantly higher in patients with RBBB. During a median follow-up of 602 days, event-free survival was significantly lower in the RBBB group (log-rank p < 0.01). RBBB was independently associated with MACE after multivariable adjustment (hazard ratio 1.465, 95% confidence interval 1.005–2.136, p = 0.047). Even in the contemporary primary PCI era, RBBB with anterior STEMI is significantly associated with worse in-hospital and long-term outcomes. RBBB may reflect more extensive myocardial injury and serve as a practical marker for risk stratification, warranting careful management and closer follow-up.
Indexed as
Identifiers
41840255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.